You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
强生新冠疫苗初步测试显示一剂疫苗可产生足够抗体
阿思达克 01-14 15:02
《新英格兰医学杂志》刊载研究报告指,强生(JNJ.US)研发的新冠疫苗安全,且一剂量疫苗足够使年轻人及长者拥有良好的免疫反应。

报告指,强生安排18至55岁人士及65岁以上长者接种高浓度、低浓度疫苗或安慰剂,部分18岁至55岁人士接种两剂疫苗,大部分接种者在28日後可检测到抗体,接种57天後全部接种者体内检测到抗体,18岁至55岁人士抗体数字在至少71天内维持稳定。大部分副作用包括发热、疲倦、头痛、肌肉酸痛等,但副作用在长者群组及接受低剂量疫苗人士较少见。

公司指,首两阶段临床测试显示一剂疫苗便能产生足够的可持续抗体,有信心疫苗能对新冠病毒有效。

是次测试有805人参与,公司计划本月稍後公布第三阶段、有4.5万人参与的临床测试结果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account